読み込み中
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
前日終値
$5.75
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
日中レンジ
現在 $5.75
52週レンジ
現在 $5.75
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
45
適正価値
センチメント
63
強気
リスク
66
高リスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
日中レンジ
現在 $5.75
52週レンジ
現在 $5.75
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 6808.8万 USD | — | — | — | 47.9万 USD |
| 粗利益 | −6808.8万 USD | — | — | — | −47.9万 USD |
| 研究開発 | 1750万 USD | 7068.2万 USD | 9379万 USD | 6146.4万 USD | 4279.4万 USD |
| 販売・一般管理 | 1667.8万 USD | 2609.3万 USD | 3330.4万 USD | 3255.2万 USD | 2122.8万 USD |
| 営業費用 | 3417.8万 USD | 1.01億 USD | 1.25億 USD | 1.04億 USD | 6354.3万 USD |
| 受取利息 | — | 396.2万 USD | 763.7万 USD | 321.6万 USD | 33.7万 USD |
| 支払利息 | — | — | — | 2431.6万 USD | 3000 USD |
| 減価償却費と償却費 | 97.2万 USD | 97万 USD | 96.9万 USD | 84.5万 USD | 47.9万 USD |
| 営業利益 | −1.02億 USD | −1.01億 USD | −1.25億 USD | −1.04億 USD | −6402.2万 USD |
| 純利益 | −1.06億 USD | −9694万 USD | −1.18億 USD | −9563.9万 USD | −5485.3万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年9月18日 | 1:10 | — | — |
発効済み 2025年9月18日
1:10
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI145.14万0.00%2.3兆 USD0.03%$381.94+0.63%
Simplify Propel Opportunities ETFSURI85.84万1.13%7606.44万 USD2.82%$17.06-0.14%
Vanguard Extended Market ETFVXF65.25万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC11.74万0.01%13.17億 USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC2.17万0.00%75.58億 USD0.43%$57.813+0.20%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR2.09万0.00%455.91億 USD0.17%$84.44+0.44%
U.S. Vector Equity Portfolio ETF Class SharesDXUV9579.50.00%61.81億 USD0.26%$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC60260.00%885.96億 USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTISimplify Propel Opportunities ETFSURIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCU.S. Core Equity 1 Portfolio ETF Class SharesDCORU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
